Disease on EC 1.1.1.205 - IMP dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Novel nucleoside inhibitors of guanosine metabolism as antitumor agents.
Agranulocytosis
Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.
Arthritis, Experimental
Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419).
Arthritis, Rheumatoid
Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis.
Autoimmune Diseases
Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
Babesiosis
Mycophenolic Acid, Mycophenolate Mofetil, Mizoribine, Ribavirin, and 7-Nitroindole Inhibit Propagation of Babesia Parasites by Targeting Inosine 5'-Monophosphate Dehydrogenase.
Blast Crisis
Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells.
Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Blindness
Characterization of retinal inosine monophosphate dehydrogenase 1 in several mammalian species.
Investigating the Mechanism of Disease in the RP10 Form of Retinitis Pigmentosa.
Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.
Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration?
Brain Neoplasms
Increased inosine-5'-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines.
Breast Neoplasms
Engineering targeted chromosomal amplifications in human breast epithelial cells.
Growth inhibition and induction of phenotypic alterations by tiazofurin: differential effects on MCF-7 breast cancer and HBL-100 breast cell lines.
Growth inhibition and induction of phenotypic alterations in MCF-7 breast cancer cells by an IMP dehydrogenase inhibitor.
Novel Direct Targets of miR-19a Identified in Breast Cancer Cells by a Quantitative Proteomic Approach.
Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.
Carcinogenesis
Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis.
Mutagen-induced resistance to mycophenolic acid in hamster cells can be associated with increased inosine 5'-phosphate dehydrogenase activity.
Carcinoma
Differential sensitivity of ovarian carcinoma cell lines to apoptosis induced by the IMPDH inhibitor benzamide riboside.
Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
Inhibitory effect of curcumin on IMP dehydrogenase, the target for anticancer and antiviral chemotherapy agents.
New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl piperonylate, as an inhibitor of purine synthesis and its activation by adenine phosphoribosyltransferase.
Ribavirin and quercetin synergistically downregulate signal transduction and are cytotoxic in human ovarian carcinoma cells.
Carcinoma, Bronchogenic
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.
Carcinoma, Ehrlich Tumor
Inhibitors of inosinate dehydrogenase activity in Ehrlich ascites tumor cells in vitro.
Carcinoma, Hepatocellular
Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.
Biochemical mechanisms of resistance to tiazofurin.
Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin.
Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells.
Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Enzymes of purine metabolism in cancer.
Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry.
Kinetic properties of IMP dehydrogenase purified from rat hepatoma 3924A.
Methotrexate decreases thymidine kinase activity.
Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Partial purification, properties and regulation of inosine 5'phosphate dehydrogenase in normal and malignant rat tissues.
Potentiation of antimetabolite action by dibromodulcitol in cell culture.
Purification of IMP dehydrogenase from rat hepatoma 3924A.
Recovery of the activities of IMP dehydrogenase and GMP synthase after treatment with tiazofurin and acivicin in hepatoma cells in vitro.
Selective guanosine phosphate deficiency in hepatoma cells induced by inhibitors of IMP dehydrogenase.
Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells.
Synergistic cytotoxic effect of tiazofurin and ribavirin in hepatoma cells.
Cardiomyopathy, Hypertrophic
CBS domains: structure, function, and pathology in human proteins.
Coinfection
Coinfection of rats with genetically diverse forms of Pneumocystis carinii demonstrated by P. carinii inosine monophosphate dehydrogenase gene polymorphism.
Colonic Neoplasms
Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells.
Colorectal Neoplasms
Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis.
Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin.
Confusion
Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides.
Connective Tissue Diseases
Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis.
Cryptosporidiosis
Inosine 5'-Monophosphate Dehydrogenase (IMPDH) as a Potential Target for the Development of a New Generation of Antiprotozoan Agents.
Triazole inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase.
Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.
Cytomegalovirus Infections
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
Diabetes Mellitus
Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients.
Inosine monophosphate dehydrogenase expression and activity are significantly lower in kidney transplant recipients with diabetes mellitus.
DNA Virus Infections
Highlights in the development of new antiviral agents.
Drug-Related Side Effects and Adverse Reactions
Mycophenolate sodium: tolerability and efficacy in transplantation in the rat.
Encephalomyelitis, Autoimmune, Experimental
Suppression of acute experimental allergic encephalomyelitis in Lewis rats with a mycophenolic acid derivative.
Genetic Diseases, Inborn
CBS domains: structure, function, and pathology in human proteins.
Glioblastoma
Purine metabolism of human glioblastoma in vivo.
Glioma
Autophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition-induced apoptotic death.
Detection of apoptosis and phagocytosis in vitro in C6 rat glioma cells treated with tiazofurin.
Reduction in beta-adrenergic response of cultured glioma cells following depletion of intracellular GTP.
Glomerulonephritis
Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
Mycophenolate mofetil prevents autoimmune glomerulonephritis and alterations of intrarenal adrenomedullin in rats.
Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.
Gout
Characterization of mutant murine lymphoma cells with altered inosinate dehydrogenase activities.
Graft vs Host Disease
Genetic Variations in the Mycophenolate Mofetil Target Enzyme Are Associated with Acute GVHD Risk after Related and Unrelated Hematopoietic Cell Transplantation.
Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.
The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.
Hematologic Neoplasms
Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion.
Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
Hepatitis
Ribavirin: recent insights into antiviral mechanisms of action.
Hepatitis C
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)--the major therapeutic target.
Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C.
In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection.
Mechanism of action of ribavirin in the treatment of chronic hepatitis C.
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
Hepatitis C, Chronic
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C.
The effects of HCV infection and management on health-related quality of life.
Herpes Simplex
Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction.
Herpesviridae Infections
Guanosine analogues as anti-herpesvirus agents.
HIV Infections
Highlights in the development of new antiviral agents.
Hypersensitivity
Separate domains of fission yeast Cdk9 (P-TEFb) are required for capping enzyme recruitment and primed (Ser7-phosphorylated) Rpb1 carboxyl-terminal domain substrate recognition.
hypoxanthine phosphoribosyltransferase deficiency
The IMP dehydrogenase catalysed reaction in erythrocytes of normal individuals and patients with hypoxanthine guanine phosphoribosyltransferase deficiency.
imp dehydrogenase deficiency
IMP dehydrogenase deficiency in Leishmania donovani causes a restrictive growth phenotype in promastigotes but is not essential for infection in mice.
Infection
A putative role for inosine 5' monophosphate dehydrogenase (IMPDH) in Leishmania amazonensis programmed cell death.
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.
Highlights in the development of new antiviral agents.
IMP dehydrogenase deficiency in Leishmania donovani causes a restrictive growth phenotype in promastigotes but is not essential for infection in mice.
Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T>C gene polymorphism.
Mycophenolic Acid, Mycophenolate Mofetil, Mizoribine, Ribavirin, and 7-Nitroindole Inhibit Propagation of Babesia Parasites by Targeting Inosine 5'-Monophosphate Dehydrogenase.
Pharmacotherapy of respiratory syncytial virus infection.
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
Structure of Cryptosporidium IMP dehydrogenase bound to an inhibitor with in vivo antiparasitic activity.
Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH.
Suppressing dengue-2 infection by chemical inhibition of Aedes aegypti host factors.
The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors.
The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.
[Effect of Epstein-Barr virus reactivation on gene expression profile of nasopharyngeal carcinoma]
Inflammatory Bowel Diseases
IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
The Role of Inosine-5'-Monophosphate Dehydrogenase in Thiopurine Metabolism in Patients With Inflammatory Bowel Disease.
Influenza, Human
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
Highlights in the development of new antiviral agents.
Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
Leber Congenital Amaurosis
Characterization of retinal inosine monophosphate dehydrogenase 1 in several mammalian species.
Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.
Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration?
Lesch-Nyhan Syndrome
Inosinic acid dehydrogenase activity in the Lesch-Nyhan syndrome.
The IMP dehydrogenase catalysed reaction in erythrocytes of normal individuals and patients with hypoxanthine guanine phosphoribosyltransferase deficiency.
Leukemia
3-Hydrogenkwadaphnin targets inosine 5'-monophosphate dehydrogenase and triggers post-G1 arrest apoptosis in human leukemia cell lines.
3-Hydrogenkwadaphnine, a novel diterpene ester from Dendrostellera lessertii, its role in differentiation and apoptosis of KG1 cells.
Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase.
Analysis of the in vitro inhibition of murine and human tumor cell growth by pyrazole derivatives and a substituted azabicyclo [3.1.0] hexane-2,4-dione.
Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin.
Chromatographic analysis of purine precursors in mouse L1210 leukemia.
Differentiation induction in non-lymphocytic leukemia cells upon treatment with mizoribine.
Discovery of N-(2,3,5-triazoyl)mycophenolic amide and mycophenolic epoxyketone as novel inhibitors of human IMPDH.
Distinct MAPK signaling pathways, p21 up-regulation and caspase-mediated p21 cleavage establishes the fate of U937 cells exposed to 3-hydrogenkwadaphnin: differentiation versus apoptosis.
E. coli gpt gene expression effects on K562 human leukemia cell proliferation and erythroid differentiation altered by mycophenolic acid.
Effects of 3-Hydrogenkwadaphnin on intracellular purine nucleotide contents and their link to K562 cell death.
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Expression of memory to the terminal differentiation inducing activity of tiazofurin in HL-60 leukemia cells.
Guanosine supplementation in K562 cells reduces the anti-proliferative and apoptotic effects of Gnidilatimonoein isolated from Daphne mucronata.
IMP dehydrogenase and GTP as targets in human leukemia treatment.
Implications of selective type II IMP dehydrogenase (IMPDH) inhibition by the 6-ethoxycarbonyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones on tumor cell death.
Increased inosine-5'-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines.
Induction of cell differentiation by IMPDH antisense oligomer in HL-60 and K562 human leukemia cell lines.
Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
Intracellular GTP level determines cell's fate toward differentiation and apoptosis.
Involvement of ERK/MAPK pathway in megakaryocytic differentiation of K562 cells induced by 3-hydrogenkwadaphnin.
Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Reciprocal alterations of GMP reductase and IMP dehydrogenase activities during differentiation in HL-60 leukemia cells.
Selection and characterization of mycophenolic acid-resistant leukemia cells.
Selective inhibition of human Molt-4 leukemia type II inosine 5'-monophosphate dehydrogenase by the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones.
Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias.
Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity.
Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity.
Synergistic cytotoxic effect of tiazofurin and ribavirin in hepatoma cells.
Synthesis and antineoplastic activity of some cyano-, carboxy-, carbomethoxy-, and carbamoylborane adducts of heterocyclic amines.
Targeting of human Tmolt4 leukemic type II IMP dehydrogenase by cyclic imide related derivatives.
The cytotoxicity and mode of action of 2,3,4-trisubstituted pyrroles and related derivatives in human Tmolt4 leukemia cells.
The cytotoxicity of N-substituted diphenimides and 6,7-dihydro-5H-dibenz[c,e]azepines.
The IMP dehydrogenase inhibitor mycophenolic acid antagonizes the CTP synthetase inhibitor 3-deazauridine in MOLT-3 human leukemia cells: a central role for phosphoribosyl pyrophosphate.
Tmolt4 leukemic type II isoform of IMP dehydrogenase as a target for 1,2,4-triazolidine-3,5-diones, 1-(1-(3-methylphenyl)ethylidineamino)-4,4-diethyl-3,5-azetidinediones, 3,5-isoxazolidinediones, and 4,4-disubstituted-3,5-pyrazolidinediones.
Leukemia, Erythroblastic, Acute
IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
Leukemia, Lymphocytic, Chronic, B-Cell
The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells.
Leukemia, Lymphoid
Cytotoxicity and mode of action of aliphatic dicarboxylic acids in L1210 lymphocytic leukemia cells.
The anti-neoplastic activity of 2,3-dihydrophthalazine-1,4-dione and N-butyl-2,3-dihydrophthalazine-1,4-dione in human and murine tumor cells.
The cytotoxicity of copper(II) complexes of heterocyclic thiosemicarbazones and 2-substituted pyridine N-oxides.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Leukemia, Myeloid
Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.
Inosine monophosphate dehydrogenase and myeloid cell maturation.
Leukemia, T-Cell
Targeting of human Tmolt4 leukemic type II IMP dehydrogenase by cyclic imide related derivatives.
Lupus Erythematosus, Systemic
ANNALS EXPRESS: Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
Mycophenolic acid upregulates miR-142-3P/5P and miR-146a in lupus CD4+T cells.
Lupus Nephritis
[Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice].
Lyme Disease
Crystal structure at 2.4 A resolution of Borrelia burgdorferi inosine 5'-monophosphate dehydrogenase: evidence of a substrate-induced hinged-lid motion by loop 6.
Expression, purification, and characterization of inosine 5'-monophosphate dehydrogenase from Borrelia burgdorferi.
Lymphocele
Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature.
Lymphoma
Analysis of purine ribonucleotides and deoxyribonucleotides in cell extracts by high-performance liquid chromatography.
Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
Characterization of mutant murine lymphoma cells with altered inosinate dehydrogenase activities.
Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole.
Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin-treated patients using a high performance liquid chromatography linked method.
Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells.
Lymphopenia
Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
Macular Degeneration
Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.
Melanoma
Characterization of human melanoma cell lines and melanocytes by proteome analysis.
Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.
Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity.
Multiple Myeloma
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Myotonia
CBS domains: structure, function, and pathology in human proteins.
Neoplasm Metastasis
Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo.
Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Neoplasm, Residual
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
Neoplasms
A new assay for intracellular measurement of inosine monophosphate dehydrogenase activity: a guide for better selection of patients for enzyme-targeted chemotherapy.
An insight to the dynamics of conserved water molecular triad in IMPDH II (human): recognition of cofactor and substrate to catalytic Arg 322.
Analysis of the in vitro inhibition of murine and human tumor cell growth by pyrazole derivatives and a substituted azabicyclo [3.1.0] hexane-2,4-dione.
Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo.
Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells.
Antitumor activity of tiazofurin in human colon carcinoma HT-29.
Autophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition-induced apoptotic death.
Bacillus anthracis Inosine 5'-Monophosphate Dehydrogenase in Action: The First Bacterial Series of Structures of Phosphate Ion-, Substrate-, and Product-Bound Complexes.
Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells.
Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells.
Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin.
Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Conserved water mediated H-bonding dynamics of inhibitor, cofactor, Asp 364 and Asn 303 in human IMPDH II.
Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin.
Cytotoxicity and mode of action of 1-(1-cyclohexenyl) and 1-unsubstituted 3,5-pyrazolidinediones in human Molt4 T cell leukemia.
Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid.
Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin.
Determination of thiazole-4-carboxamide adenine dinucleotide (TAD) levels in mononuclear cells of leukemic patients treated with tiazofurin.
Differential Sensitivities of Fast- and Slow-cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid.
Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5'-monophosphate dehydrogenase.
Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation.
Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer.
Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Glutamine deprivation initiates reversible assembly of mammalian rods and rings.
Guanosine analogues as anti-herpesvirus agents.
Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis.
Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis.
IMP dehydrogenase : structural aspects of inhibitor binding.
IMP dehydrogenase, an enzyme linked with proliferation and malignancy.
IMP dehydrogenase. II. Purification and properties of the enzyme from Yoshida sarcoma ascites tumor cells.
Implications of selective type II IMP dehydrogenase (IMPDH) inhibition by the 6-ethoxycarbonyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones on tumor cell death.
Increased inosine-5'-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines.
Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
Inhibitors of inosinate dehydrogenase activity in Ehrlich ascites tumor cells in vitro.
Inosine 5'-monophosphate dehydrogenase inhibitors as antimicrobial agents: recent progress and future perspectives.
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).
Interpopulation variation frequency of human inosine 5'-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms.
Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: potent inhibitors of human type II inosine 5'-monophosphate dehydrogenase.
Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside.
Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis.
Mycophenolic acid inhibits migration and invasion of gastric cancer cells via multiple molecular pathways.
Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145.
NAD-based inhibitors with anticancer potential.
Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
Novel nucleoside inhibitors of guanosine metabolism as antitumor agents.
Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents.
Partial purification, properties and regulation of inosine 5'phosphate dehydrogenase in normal and malignant rat tissues.
Purification of IMP dehydrogenase from rat hepatoma 3924A.
Purification, characterization, and kinetic analysis of inosine 5'-monophosphate dehydrogenase of Tritrichomonas foetus.
Purine metabolism of human glioblastoma in vivo.
Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
Regulation of GTP biosynthesis.
Ribavirin as a tri-targeted antitumor repositioned drug.
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
Role of differentiation induction in action of purine antimetabolites.
Selective inhibition of human Molt-4 leukemia type II inosine 5'-monophosphate dehydrogenase by the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones.
Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias.
Sensitive radiochemical assay for inosine 5'-monophosphate dehydrogenase and determination of activity in murine tumor and tissue extracts.
Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.
Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo.
Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase.
Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
Synergistic activity of purine metabolism inhibitors in cultured human tumor cells.
The chemistry of nicotinamide adenine dinucleotide (NAD) analogues containing C-nucleosides related to nicotinamide riboside.
The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells.
The role of IMP dehydrogenase 2 in Inauhzin-induced ribosomal stress.
Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogues stable to phosphodiesterase hydrolysis.
Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Tiazofurin: biological effects and clinical uses.
Tiazofurin: molecular and clinical action.
Transcriptomic changes induced by mycophenolic acid in gastric cancer cells.
[Nucleotide metabolism in human glioma: comparative study of primary tumors, grafted tumors on nude mice and cell cultures]
Nephrotic Syndrome
[Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report]
Neuroblastoma
Biological effects of inhibition of guanine nucleotide synthesis by mycophenolic acid in cultured neuroblastoma cells.
Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells.
Gene amplification and dual point mutations of mouse IMP dehydrogenase associated with cellular resistance to mycophenolic acid.
Guanine nucleotide depletion induces differentiation and aberrant neurite outgrowth in human dopaminergic neuroblastoma lines: a model for basal ganglia dysfunction in Lesch-Nyhan disease.
Increased activity, amount, and altered kinetic properties of IMP dehydrogenase from mycophenolic acid-resistant neuroblastoma cells.
Increased inosinate dehydrogenase activity in mycophenolic acid resistant neuroblastoma cells.
Neutropenia
Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.
Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T>C gene polymorphism.
Novel gene polymorphisms in the impdh2 gene may account for neutropenia and other side effects in patients treated with mycophenolic Acid (mpa).
Obesity
Inhibition of inosine monophosphate dehydrogenase reduces adipogenesis and diet-induced obesity.
Osteosarcoma
IMPDH2 mediate radioresistance and chemoresistance in osteosarcoma cells.
Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells.
Prognostic significance of drug-regulated genes in high-grade osteosarcoma.
Pain
Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.
Parasitic Diseases
Crystal structure of Tritrichomonas foetus inosine-5'-monophosphate dehydrogenase and the enzyme-product complex.
Tritrichomonas foetus: a strategy for structure-based inhibitor design of a protozoan inosine-5'-monophosphate dehydrogenase.
phosphoglycerate kinase deficiency
Genome-wide identification of pseudogenes capable of disease-causing gene conversion.
Picornaviridae Infections
Highlights in the development of new antiviral agents.
Poxviridae Infections
Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: Enzymological and clinical aspects.
Prostatic Hyperplasia
Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
Prostatic Neoplasms
Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells.
Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappaB activity.
Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5'-monophosphate dehydrogenase.
Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer.
Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145.
Psoriasis
Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
Renal Insufficiency
4-Pyridone-3-carboxamide-1-?-D-ribonucleoside Triphosphate (4PyTP), a Novel NAD Metabolite Accumulating in Erythrocytes of Uremic Children: A Biomarker for a Toxic NAD Analogue in Other Tissues?
Retinal Degeneration
Autosomal dominant retinitis pigmentosa in Norway: a 20-year clinical follow-up study with molecular genetic analysis. Two novel rhodopsin mutations: 1003delG and I179F.
On the role of IMPDH1 in retinal degeneration.
Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.
Towards a pathological mechanism for IMPDH1-linked retinitis pigmentosa.
Retinal Diseases
Characterization of retinal inosine monophosphate dehydrogenase 1 in several mammalian species.
Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration?
Retinitis
Autosomal dominant retinitis pigmentosa mutations in inosine 5'-monophosphate dehydrogenase type I disrupt nucleic acid binding.
Retinitis Pigmentosa
A novel IMPDH1 mutation (Arg231Pro) in a family with a severe form of autosomal dominant retinitis pigmentosa.
Autosomal dominant retinitis pigmentosa in Norway: a 20-year clinical follow-up study with molecular genetic analysis. Two novel rhodopsin mutations: 1003delG and I179F.
Autosomal dominant retinitis pigmentosa mutations in inosine 5'-monophosphate dehydrogenase type I disrupt nucleic acid binding.
CBS domains: structure, function, and pathology in human proteins.
Characterisation of inosine monophosphate dehydrogenase expression during retinal development: differences between variants and isoforms.
Characterization of retinal inosine monophosphate dehydrogenase 1 in several mammalian species.
Clinical phenotype in a Swedish family with a mutation in the IMPDH1 gene.
Detection of novel mutations that cause autosomal dominant retinitis pigmentosa in candidate genes by long-range PCR amplification and next-generation sequencing.
Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms.
Genome-wide identification of pseudogenes capable of disease-causing gene conversion.
Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice.
Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state.
Molecular recruitment as a basis for negative dominant inheritance? Propagation of misfolding in oligomers of IMPDH1, the mutated enzyme in the RP10 form of retinitis pigmentosa.
Mutation Frequency of IMPDH1 Gene of Han Population in Ganzhou City.
Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa.
Phenotypic characterization of a large family with RP10 autosomal-dominant retinitis pigmentosa: an Asp226Asn mutation in the IMPDH1 gene.
Protection of Photoreceptors in a Mouse Model of RP10.
Retinal isoforms of inosine 5'-monophosphate dehydrogenase type 1 are poor nucleic acid binding proteins.
Retinitis pigmentosa: mutation analysis of RHO, PRPF31, RP1, and IMPDH1 genes in patients from India.
Screen of the IMPDH1 gene among patients with dominant retinitis pigmentosa and clinical features associated with the most common mutation, Asp226Asn.
Screening for mutations in the IMPDH1 gene in Japanese patients with autosomal dominant retinitis pigmentosa.
Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis.
The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover.
Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).
Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration?
Sarcoma
Conserved water mediated recognition and the dynamics of active site Cys 331 and Tyr 411 in hydrated structure of human IMPDH-II.
IMP dehydrogenase. II. Purification and properties of the enzyme from Yoshida sarcoma ascites tumor cells.
Increased inosine-5'-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines.
Purification, characterization, and kinetic analysis of inosine 5'-monophosphate dehydrogenase of Tritrichomonas foetus.
Sarcoma 180
Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
Inhibition of inosinic acid dehydrogenase of sarcoma 180 ascites cells by nucleotides and their analogs.
Inosine 5'-monophosphate dehydrogenase from sarcoma 180 cells-substrate and inhibitor specificity.
Inosinic acid dehydrogenase of sarcoma 180 cells.
Sarcoma, Yoshida
IMP dehydrogenase. II. Purification and properties of the enzyme from Yoshida sarcoma ascites tumor cells.
Severe Acute Respiratory Syndrome
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.
Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.
Smallpox
Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives.
Starvation
The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover.
Stomach Neoplasms
ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2.
Systemic Vasculitis
Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid.
Testicular Neoplasms
Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer.
Tuberculosis
Carbocyclic analogues of inosine-5'-monophosphate: synthesis and biological activity.
Identification of novel diphenyl urea inhibitors of Mt-GuaB2 active against Mycobacterium tuberculosis.
Identification of novel Mt-Guab2 inhibitor series active against M. tuberculosis.
Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery.
Mycobacterium tuberculosis IMPDH in Complexes with Substrates, Products and Antitubercular Compounds.
Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen.
The Bare Essentials of Antibiotic Target Validation.
The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.
Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis.
Ureteral Obstruction
Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on renal fibrosis in unilateral ureteral obstruction in rats.
Urinary Bladder Neoplasms
Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer.
Urologic Neoplasms
Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer.
Uterine Cervical Neoplasms
Oxymatrine induces apoptosis in human cervical cancer cells through guanine nucleotide depletion.
Virus Diseases
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)--the major therapeutic target.
Hamao Umezawa Memorial Award Lecture: "An Odyssey in the Viral Chemotherapy Field".
Highlights in the development of new antiviral agents.
Inosine 5'-monophosphate dehydrogenase inhibitors as antimicrobial agents: recent progress and future perspectives.
Wiskott-Aldrich Syndrome
Dissection of the molecular basis of mycophenolate resistance in Saccharomyces cerevisiae.
IMP dehydrogenase is recruited to the transcription complex through serine 2 phosphorylation of RNA polymerase II.
Regulation of an IMP dehydrogenase gene and its overexpression in drug-sensitive transcription elongation mutants of yeast.
Screening the yeast "disruptome" for mutants affecting resistance to the immunosuppressive drug, mycophenolic acid.